PDF电子书：Therapeutic Oligonucleotides (Springer MMB-V764, 2011).pdf

xyklmu

0 p6 y0 E) n  w3 q( y# `- ~
( _4 r" {% O. O/ K* G8 m
[hide][/hide]1 w: V! y" j! k2 |: g
Therapeutic Oligonucleotides0 G/ [7 y" u0 u# O* O, {& u- |: n' l
Methods and Protocols   Springer MMB-V764, 2011     
0 n$ l) k6 \. X) \: ]Edited by
4 o. z5 U% {+ X3 l, n2 ~3 ]John Goodchild' \0 ?+ y5 i+ }! v+ R
Department of Chemistry, Worcester State University,Worcester, MA, USA5 b2 M8 x) S/ d7 f8 W9 j
- J1 W0 Q: A9 ?. b8 d% ^( [
Contents
4 `1 G: |/ {2 U2 S( E7 I4 uPreface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v
0 S$ K3 B+ }# n" pContributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix( w  E) V2 V- h5 b) \, W2 y
1. Therapeutic Oligonucleotides . . . . . . . . . . . . . . . . . . . . . . . . . . . 1$ J9 Q, N7 N7 H6 U
John Goodchild
' i& Z$ T& {: @2 |. ?! H) ]& f2. Dinucleotides Containing 3-S-Phosphorothiolate Linkages . . . . . . . . . . . . 17+ Y4 F( T7 U# B' k/ V
James W. Gaynor and Richard Cosstick2 g  Q/ {  X1 C- o. y! v' h
3. 2-O,4-C-Methyleneoxymethylene Bridged Nucleic Acids (2,4-BNACOC) . . . . 315 A# a0 m7 s3 k; h
Yoshiyuki Hari, Tetsuya Kodama, Takeshi Imanishi,/ W3 G* Q6 E( I# c7 P1 r
and Satoshi Obika
" @# @% V+ ~) M2 \" E# V* H4. A Non-covalent Peptide-Based Strategy for Ex Vivo and In Vivo- V5 H1 A% M( o* X- c5 s. ], c
Oligonucleotide Delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
& h0 T( |+ }( W. S, ~5 ALaurence Crombez, May C. Morris, Frederic Heitz, and Gilles Divita
0 a' r- y, n( I9 S" l3 [5. Cell-Penetrating Peptides-Based Strategies for the Delivery of Splice
6 ~9 r- Y/ {* D2 E4 ~Redirecting Antisense Oligonucleotides . . . . . . . . . . . . . . . . . . . . . . 756 n, h1 T  t- [& L3 o& S
Samir El Andaloussi, Fatouma Said Hassane, Prisca Boisguerin,9 m# E& B$ u7 z! c! P
Rannar Sillard, Ülo Langel, and Bernard Lebleu% U7 {) y) P* Q
6. A Nanoparticle for Tumor Targeted Delivery of Oligomers . . . . . . . . . . . . 91
8 `7 v# H% D6 J2 w# ^Xinrong Liu, Yi Wang, and Donald J. Hnatowich
8 x  B9 O! h+ L, C6 l: j7. Light-Directed Delivery of Nucleic Acids . . . . . . . . . . . . . . . . . . . . . 107
' g- M! B; o' v2 GSigurd Bøe, Lina Prasmickaite, Birgit Engesæter, and Eivind Hovig
* S0 ]) @3 L# }$ C: o/ Q8. Antibody Targeted siRNA Delivery . . . . . . . . . . . . . . . . . . . . . . . . 123* B% R/ M. l6 x& d! j
Masoud M. Toloue and Lance P. Ford# ?* z/ _* J2 R& {
9. Aptamer–Drug Conjugation for Targeted Tumor Cell Therapy . . . . . . . . . . 141
) n/ K& |2 S1 U  {( Z3 yMichael J. Donovan, Ling Meng, Tao Chen, Yunfei Zhang,% A0 Q% _# d) Y% l. @
Kwame Sefah, and Weihong Tan9 ~+ `5 `+ I; U: z, d
10. Five-Step Process for Screening Antisense Compounds for Efficacy: Gene
4 c9 g$ ~& s8 `Target IL-12Rb2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
& Z# d% B4 n' F/ JNikki B. Marshall, Laura L. Hauck, and Dan V. Mourich
# g* b' G) H) Z# d. R11. Diverse Small Non-coding RNAs in RNA Interference Pathways . . . . . . . . . 169
9 j& f8 @5 r, q  J* Q, uLiande Li and Yi Liu* Y. Y6 ~6 J( l+ O
12. Quantification of siRNAs In Vitro and In Vivo . . . . . . . . . . . . . . . . . . . 183/ ?  |- h3 q) t" Z/ ?1 @
Angie Cheng, Alexander V. Vlassov, and Susan Magdaleno
2 g* o" ~+ [% h7 A5 K4 ~+ vvii0 x; v, U! Z! ]3 P- t' L  ?/ V
viii Contents; B7 T( D5 w# O; P4 t1 K+ {: X
13. Optimization of Transfection Conditions and Analysis of siRNA Potency
/ D9 e0 l8 V1 _" p7 d) |& ZUsing Real-time PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1996 z- ?: w; V9 z1 Q/ T  ]# ^
Angie Cheng, Susan Magdaleno, and Alexander V. Vlassov
8 _7 T( [' F; Z9 ~3 h14. siRNA Knockdown of Gene Expression in Endothelial Cells . . . . . . . . . . . . 215
  I" g  W& u7 Q6 CEmily Dennstedt and Brad Bryan
3 T) J( k5 n- p9 q0 [% h15. Using RNA Interference in Schistosoma mansoni . . . . . . . . . . . . . . . . . . 223
' b2 s$ M# e5 Q& m9 r: y, ]Rita Bhardwaj, Greice Krautz-Peterson, and Patrick J. Skelly4 p/ F$ [" T) x+ a8 @  v
16. Performing the Labeled microRNA Pull-Down (LAMP) Assay System:
" m, ]" |7 O/ o; c8 T, w$ K! nAn Experimental Approach for High-Throughput Identification of
7 `' f3 z& }# l0 t) umicroRNA-Target mRNAs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 241
2 K1 M* J' K% ]2 _Ren-Jun Hsu and Huai-Jen Tsai0 p6 R# _/ p: h7 ]
17. Synthesis, Purification, and Characterization of Oligoribonucleotides that
8 D% H# K  J" r( X: zAct as Agonists of TLR7 and/or TLR8 . . . . . . . . . . . . . . . . . . . . . . 249
' h0 U2 C3 a: `( C5 XTao Lan and Ekambar R. Kandimalla' V6 ~  v. x5 i; {
18. Synthesis, Purification, and Characterization of Immune-Modulatory  I1 d+ f0 n& l; a; g0 L
Oligodeoxynucleotides that Act as Agonists of Toll-Like Receptor 9 . . . . . . . . 263
' c3 [; k0 ~' T( w6 t3 ^7 S$ g5 R$ ]# EMallikarjuna Reddy Putta, Dong Yu, and Ekambar R. Kandimalla& u2 X* T" J, `7 b, G& W+ C8 I
19. Surface Plasmon Resonance Investigation of RNA Aptamer–RNA Ligand
  o! c/ x( }* e4 `% c5 d% [Interactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2799 K( o% N2 a, d
Carmelo Di Primo, Eric Dausse, and Jean-Jacques Toulmé
) d4 a) _3 C4 O0 c* v20. Practical Considerations for Analyzing Antigene RNAs (agRNAs): RNA4 Z2 k' F8 r6 Y; {4 E% P3 f
Immunoprecipitation of Argonaute Protein . . . . . . . . . . . . . . . . . . . . 301( @# A: k% {2 \- L3 k  [
Jacob C. Schwartz and David R. Corey
# R! V0 \# Y+ M! j21. Inhibition of Human Papillomavirus Expression Using DNAzymes . . . . . . . . 317
- z8 f- v' Q- E7 J1 G3 P( F' KMaría Luisa Benítez-Hess, Pablo Reyes-Gutiérrez,
* R4 |/ V% i) J1 t8 d) {. M( E5 Zand Luis Marat Alvarez-Salas
3 w4 Z0 |+ _  j; j8 p% K1 }5 ^Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 337

hualin

ziyumo

nice

bluesuns

呵呵 高高实在是高~~~~~  

dypnr

谢谢分享了!  

sky蓝

勤奋真能造就财富吗？  

foxok

慢慢来，呵呵  

石头111

呵呵 大家好奇嘛 来观看下~~~~  

罗马星空

我起来了 哈哈 刚才迷了会  

科研人

我的啦嘿嘿